SITE011-0011

SITE011 (ITA) › SITE011-0011

SITE011-0011

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2025-08-30

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-23 (study day 317); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.